OncoMatch/Clinical Trials/NCT06319820
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Is NCT06319820 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including TAR-210 and Gemcitabine for non-muscle invasive bladder neoplasms.
Treatment: TAR-210 · Gemcitabine · MMC — The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Biomarker criteria
Required: FGFR susceptible mutation
Have a susceptible fibroblast growth factor receptor (FGFR) mutation or fusion either by urine testing or tumor tissue testing (from TURBT tissue), as determined by central or local testing
Required: FGFR fusion
Have a susceptible fibroblast growth factor receptor (FGFR) mutation or fusion either by urine testing or tumor tissue testing (from TURBT tissue), as determined by central or local testing
Disease stage
Grade: low gradegrade 1grade 2
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Arkansas Urology · Little Rock, Arkansas
- Genesis Research LLC · Los Alamitos, California
- USC Norris Comprehensive Cancer Center · Los Angeles, California
- University of California Irvine Medical Center · Orange, California
- Om Research LLC · San Diego, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify